A community based cross sectional study on the prevalence of dyslipidemias and 10 years cardiovascular risk scores in adults in Asmara, Eritrea.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 04 2022
Historique:
received: 06 07 2021
accepted: 17 03 2022
entrez: 3 4 2022
pubmed: 4 4 2022
medline: 6 4 2022
Statut: epublish

Résumé

Despite the contribution of dyslipidemia to the high and rising burden of arteriosclerotic cardiovascular disease (CVD) in Sub-Saharan Africa; the condition is under-diagnosed, under-treated, and under-described. The objective of this study was to explore the prevalence of dyslipidemias, estimate a 10-year cardiovascular disease risk and associated factors in adults (≥ 35 to ≤ 85 years) living in Asmara, Eritrea. This population-based cross-sectional study was conducted among individuals without overt CVDs in Asmara, Eritrea, from October 2020 to November 2020. After stratified multistage sampling, a total of 386 (144 (37%) males and 242 (63%) females, mean age ± SD, 52.17 ± 13.29 years) respondents were randomly selected. The WHO NCD STEPS instrument version 3.1 questionnaire was used to collect data. Information on socio-demographic variables was collected via interviews by trained data collectors. Measurements/or analyses including anthropometric, lipid panel, fasting plasma glucose, and blood pressure were also undertaken. Finally, data was analyzed by using Statistical Package for Social Sciences version 26.0 for Windows (SPSS Inc., Chicago, IL, USA). All p-values were 2-sided and the level of significance was set at p < 0.05 for all analyses. The frequency of dyslipidemia in this population was disproportionately high (87.4%) with the worst affected subgroup in the 51-60 age band. Further, 98% of the study participants were not aware of their diagnosis. In terms of individual lipid markers, the proportions were as follows: low HDL-C (55.2%); high TC (49.7%); high LDL (44.8%); high TG (38.1%). The mean ± SD, for HDL-C, TC, LDL-C, non-HDL-C, and TG were 45.28 ± 9.60; 205.24 ± 45.77; 130.77 ± 36.15; 160.22 ± 42.09 and 144.5 ± 61.26 mg/dL, respectively. Regarding NCEP ATP III risk criteria, 17.6%, 19.4%, 16.3%, 19.7%, and 54.7% were in high or very high-risk categories for TC, Non-HDL-C, TG, LDL-C, and HDL-C, respectively. Among all respondents, 59.6% had mixed dyslipidemias with TC + TG + LDL-C dominating. In addition, 27.3%, 28.04%, 23.0%, and 8.6% had abnormalities in 1, 2, 3 and 4 lipid abnormalities, respectively. Multivariate logistic regression modeling suggested that dyslipidemia was lower in subjects who were employed (aOR 0.48, 95% CI 0.24-0.97, p = 0.015); self-employed (aOR 0.41, 95% CI 0.17-1.00, p = 0.018); and married (aOR 2.35, 95% CI 1.19-4.66, p = 0.009). A higher likelihood of dyslipidemia was also associated with increasing DBP (aOR 1.04 mmHg (1.00-1.09, p = 0.001) and increasing FPG (aOR 1.02 per 1 mg/dL, 95% CI 1.00-1.05, p = 0.001). Separately, Framingham CVD Risk score estimates suggested that 12.7% and 2.8% were at 10 years CVD high risk or very high-risk strata. High frequency of poor lipid health may be a prominent contributor to the high burden of atherosclerotic CVDs-related mortality and morbidity in Asmara, Eritrea. Consequently, efforts directed at early detection, and evidence-based interventions are warranted. The low awareness rate also points at education within the population as a possible intervention pathway.

Identifiants

pubmed: 35368036
doi: 10.1038/s41598-022-09446-9
pii: 10.1038/s41598-022-09446-9
pmc: PMC8976836
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5567

Informations de copyright

© 2022. The Author(s).

Références

Eur J Prev Cardiol. 2014 Jun;21(6):682-91
pubmed: 22952291
Endocr Pract. 2017 Apr;23(Suppl 2):1-87
pubmed: 28437620
PLoS One. 2017 Oct 27;12(10):e0187347
pubmed: 29077762
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
Lancet. 2012 Aug 11;380(9841):572-80
pubmed: 22607825
Lipids Health Dis. 2018 Apr 19;17(1):88
pubmed: 29673349
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
BMJ Open. 2015 Dec 11;5(12):e007954
pubmed: 26656980
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
Blood Press Suppl. 1999;1:9-43
pubmed: 10401540
Cardiovasc J Afr. 2015 Mar-Apr;26(2 Suppl 1):S27-38
pubmed: 25962945
PLoS One. 2014 May 09;9(5):e96808
pubmed: 24817067
J Clin Invest. 1994 Dec;94(6):2377-84
pubmed: 7989594
Stroke. 2018 May;49(5):1116-1122
pubmed: 29618553
JAMA. 1986 Nov 28;256(20):2823-8
pubmed: 3773199
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
PLoS One. 2021 Feb 9;16(2):e0243103
pubmed: 33561153
Lancet. 2008 Jul 19;372(9634):224-33
pubmed: 18640459
Lancet. 2008 Mar 15;371(9616):915-22
pubmed: 18342686
Eur Heart J. 2011 Jun;32(11):1345-61
pubmed: 21531743
Public Health. 2020 Jan;178:167-178
pubmed: 31698139
Circulation. 2001 Dec 18;104(25):3046-51
pubmed: 11748098
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
BMJ Glob Health. 2021 May;6(5):
pubmed: 34016577
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Aging Clin Exp Res. 2017 Apr;29(2):319-326
pubmed: 26931325
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
PLoS One. 2014 Aug 04;9(8):e102830
pubmed: 25090638
Eur J Cardiovasc Prev Rehabil. 2011 Feb;18(1):97-105
pubmed: 21354969
Lancet. 2014 Aug 16;384(9943):626-635
pubmed: 25131982
J Diabetes Res. 2020 Jan 28;2020:5901569
pubmed: 32090121
J Clin Lab Anal. 2018 Oct;32(8):e22579
pubmed: 29926995
Lancet Glob Health. 2018 Sep;6(9):e998-e1007
pubmed: 30103999
Circulation. 2005 Dec 6;112(23):3554-61
pubmed: 16330696
Vasc Health Risk Manag. 2012;8:247-54
pubmed: 22566746
J Clin Lipidol. 2012 Jul-Aug;6(4):325-30
pubmed: 22836069
Am J Epidemiol. 1989 Jan;129(1):76-88
pubmed: 2910074
J Lipid Res. 2004 Jul;45(7):1169-96
pubmed: 15102878
CVD Prev Control. 2010 Sep 1;5(3):75-80
pubmed: 21113431
PLoS One. 2018 May 9;13(5):e0194819
pubmed: 29742131
BMC Med. 2020 Jul 16;18(1):181
pubmed: 32669098
Glob Heart. 2020 Feb 12;15(1):15
pubmed: 32489788
PLoS One. 2015 May 14;10(5):e0126166
pubmed: 25974077
BMJ Open. 2019 Nov 7;9(11):e031969
pubmed: 31699740

Auteurs

Oliver Okoth Achila (OO)

Orotta College of Medicine and Health Sciences, Asmara, Eritrea.

Nahom Fessahye (N)

Orotta College of Medicine and Health Sciences, Asmara, Eritrea.

Samuel Tekle Mengistu (ST)

Orotta College of Medicine and Health Sciences, Asmara, Eritrea. teklesam7@gmail.com.
Nakfa Hospital, Ministry of Health Northern Red Sea Branch, Nakfa, Eritrea. teklesam7@gmail.com.

Naemi Tesfamariam Habtemikael (NT)

Orotta College of Medicine and Health Sciences, Asmara, Eritrea.

Wintana Yebio Werke (WY)

Orotta College of Medicine and Health Sciences, Asmara, Eritrea.

Femal Tesfazghi Zemichael (FT)

Orotta College of Medicine and Health Sciences, Asmara, Eritrea.

Haben Negash Leghese (HN)

Orotta College of Medicine and Health Sciences, Asmara, Eritrea.

Thomas Amanuel Weldegegish (TA)

Orotta College of Medicine and Health Sciences, Asmara, Eritrea.

Tsegay Habteab Tekeste (TH)

Orotta College of Medicine and Health Sciences, Asmara, Eritrea.

Eyob Yohannes Garoy (EY)

Orotta College of Medicine and Health Sciences, Asmara, Eritrea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH